Latest News Archive
Please select Category, Year, and then Month to display items
26 November 2020
|
Story Leonie Bolleurs
![]()
Mind Matters is a first for the UFS. It is a mental-health publication for students aimed at highlighting what matters most when it comes to your mind, life, and well-being. Some sections share how individuals in the top echelons of the UFS take care of their minds. Other sections focus on how to support your grey matter (i.e. your brain) and, consequently, improve your general functioning. Some parts discuss matters related to careers, well-being, finance, and self-development. We also provide news and resources that might matter to you.
Whatever your fancy, Mind Matters focuses primarily on why the health of your mind matters. Our minds and brains are the most powerful intelligence or apparatuses on the planet. A power like this needs to be wielded wisely, otherwise we may suffer much from our own neglect of our mental health. It’s not always easy, but it is important!
Mind Matters was possible due to the cumulative contributions, inputs, and work of numerous UFS professionals, especially within
Student Affairs. We are grateful and proud of each person involved. We endeavour to honour these efforts by continually improving and developing Mind Matters. Your feedback and voices are most welcome and will continue to inform what we do next.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004